Press Release

Printer Friendly Version View printer-friendly version
<< Back
T2 Biosystems Joins Antimicrobials Working Group as First Diagnostic Member

LEXINGTON, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it will join the Antimicrobials Working Group (AWG) as its first diagnostic member. T2 Biosystems joins thirteen antimicrobials companies in their mission to combat drug resistant infections and spur life-saving innovations.  

“Diagnostics play a vital role in providing the best possible patient care and combatting the global health threat of antimicrobial resistance,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara Therapeutics and Chairman of the AWG. “T2 Biosystems is a leading innovator in the field and their T2MR detection technology enables the delivery of life-saving medicines more rapidly to patients and reduces the use of unnecessary drug exposure. We’re excited to have their expertise in the fight against superbugs and drug resistant infections.”

The T2Sepsis SolutionTM is a unique approach that combines the best standard of care with T2 Biosystems’ products, including the T2Dx® Instrument and the T2Candida® Panel. The T2Sepsis Solution enables early, targeted treatment, providing clinicians the confidence to de-escalate or stop unnecessary medications. The T2Sepsis Solution is proven to reduce the time to effective treatment for patients, reduce length of stay in the hospital and ICU, and can lead to significant reductions in unnecessary medication. In addition, T2 Biosystems’ products may lead to increased enrollment and effectiveness of our partners’ clinical trials for new, potentially life-saving medication.

“Now more than ever, it is imperative to use the medications we have today in a targeted manner to prevent resistance and to hasten the development of new medications. Diagnostics play an important role in delivering patients the right treatment and assist in accelerated clinical trials.” said John McDonough, president and chief executive officer of T2 Biosystems. “Antimicrobial resistance is a multi-generational challenge and we are proud to be part of this important collaboration.”

About T2 Biosystems
T2 Biosystems is dedicated to developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance technology, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of patient sample types, including whole blood. For more information, please visit www.t2biosystems.com.

About The Antimicrobials Working Group 
AWG was founded in 2012 with the vision of utilizing collective power to improve the regulatory, investment, and commercial environment for emerging antibiotics and antifungal companies. Today, AWG is comprised of fourteen antimicrobials and diagnostics companies: Amplyx Pharmaceuticals, Arsanis Inc., Cempra Inc., Cidara Therapeutics Inc., ContraFect Corporation, Iterum Therapeutics Ltd., Melinta Therapeutics Inc., Nabriva Therapeutics US Inc., Paratek Pharmaceuticals Inc., SCYNEXIS Inc., T2 Biosystems Inc., Theravance Biopharma US Inc., Viamet Pharmaceuticals Inc., and Zavante Therapeutics Inc. For more information, please visit www.antimicrobialsworkinggroup.org.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 15, 2017, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.

Company Contact:
Darlene Deptula-Hicks, T2 Biosystems
SVP & Chief Financial Officer
ddeptula@t2biosystems.com
603-553-5803

Media Contact:
Matthew McKillip, T2 Biosystems
mmckillip@t2biosystems.com
518-577-3466

Investor Contact:
Chris Brinzey, Westwicke Partners 
chris.brinzey@westwicke.com
339-970-2843

Primary Logo

T2 Biosystems, Inc.